Vetter, a contract development and manufacturing organization, has completed construction of its new multi-functional  Schuetzenstrasse building in Ravensburg, Germany, following two years of construction to advance development and information technology (IT) capabilities. The EUR 29 million ($32 million) building is part of an EUR 300 million ($328 million) investment investment strategy announced by the company in September 2015. The Schuetzenstrasse building will support drug development and enhanced IT systems. The new 8,500 square meter building contains non-cGMP laboratories for development support, laboratory space for microbiological analysis, office workplaces for Vetter Development Service, and IT as well a data processing center with enhanced security systems, including a safety cell that protects technology and data from external physical hazards in the event of an emergency.

Vetter reported a 10% increase in sales in 2015, and the company supported nine drug approvals in North America, Europe, and Japan. In the third quarter, Vetter opened a new subsidiary in Tokyo, Japan to complement the Singapore operating branch it created in 2014. The company also launched Vetter-Ject, a closure system for prefilled syringes for use with highly sensitive compounds such as biologics.

Source: Vetter